{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:45:34Z","timestamp":1786653934079,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Primary breast neuroendocrine carcinomas (NECs) are rare, high-grade malignancies that are frequently grouped with invasive breast carcinomas with neuroendocrine differentiation (IBC-NED), despite uncertain biological equivalence. We sought to define the clinicopathologic, immunophenotypic, and genomic features of breast NEC and to determine whether they represent a biologically distinct entity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of 24 primary breast NECs and compared them with 28 grade-matched IBC-NEDs. Clinicopathologic features, treatment response, and outcomes were evaluated. Immunohistochemical profiling included neuroendocrine and breast lineage markers and retinoblastoma (Rb) expression. Targeted tumor-normal next-generation sequencing was performed in a subset of NEC (n = 10) and IBC-NED (n = 7) to characterize genomic alterations and pathway-level differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Breast NECs were predominantly estrogen receptor (ER)\u2013negative\/human epidermal growth factor receptor-2\u2013negative (63%) and frequently exhibited small cell morphology. Despite radiographic response to neoadjuvant chemotherapy, no patients achieved pathologic complete response. Immunophenotypically, NECs demonstrated diffuse neuroendocrine marker expression and frequent loss of Rb protein (93%), consistent with RB pathway disruption. Compared with IBC-NED, NECs showed significantly lower ER expression and reduced GATA3 positivity. Genomically, NECs were enriched for\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      alterations (90%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      33%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .05) and more frequently harbored\n                      <jats:italic toggle=\"yes\">RB1<\/jats:italic>\n                      alterations (60%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      14%), with concurrent\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">RB1<\/jats:italic>\n                      alterations in 50% of cases. Alterations in the PI3K pathway were also observed in NECs. By contrast, IBC-NED demonstrated recurrent luminal-type copy-number alterations, including amplifications in\n                      <jats:italic toggle=\"yes\">FGFR1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">CCND1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Breast NEC is characterized by a distinct clinicopathologic and molecular profile compared with grade-matched IBC-NED, defined by frequent\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">RB1<\/jats:italic>\n                      alterations, RB pathway disruption, and limited response to neoadjuvant therapy. These findings support classification of breast NEC as a biologically distinct subtype and highlight potential avenues for biomarker-driven therapeutic strategies in this rare malignancy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00416","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:00:12Z","timestamp":1786651212000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-8429","authenticated-orcid":true,"given":"Christopher J.","family":"Schwartz","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Mack","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Travis","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Abuhadra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-6081","authenticated-orcid":true,"given":"Risa","family":"Kiernan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3511-369X","authenticated-orcid":true,"given":"Giacomo","family":"Montagna","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fresia","family":"Pareja","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","volume-title":"Breast Tumours. WHO Classification of Tumours, 5th Edition","author":"WHO Classification of Tumours Editorial Board","year":"2019","unstructured":"WHO Classification of Tumours Editorial Board: Breast Tumours. WHO Classification of Tumours, 5th Edition. IARC, Lyon, 2019"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0309"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1743-9191(13)60023-0"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.107"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_2.S115"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2946"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01090-y"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-025-09854-3"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0904-SA"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0187-ED"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100541"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-025-01623-4"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.009"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.12.006"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/his.12287"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181f884e8"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100936"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae372"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001529"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-025-07854-9"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:00:15Z","timestamp":1786651215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-26-00416"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00416","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600416"}}